NCT04372355View on ClinicalTrials.gov

Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

June 19, 2020

Conditions
Diabetic Foot Ulcer (DFU)Uncontrolled Diabetes With Foot Ulcer
Interventions
DRUG

WF10

WF10, the chlorite-based drug is infused at a dose of 0.3 ml/Kg BW, after dilution in 300 mL physiological saline, over a period of 3 h. The drug is applied once a week for five subsequent weeks.

Trial Locations (1)

26120

HRH Princess Maha Chakri Sirindhorm Medical Center, Ongkharak

All Listed Sponsors
collaborator

Oxo Chemie(Thailand) Co.,Ltd.

UNKNOWN

collaborator

Altermed Co.,Ltd.

UNKNOWN

lead

Srinakharinwirot University

OTHER

NCT04372355 - Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients | Biotech Hunter | Biotech Hunter